Ozempic Gastroparesis Attorney: Eligibility Overview for Legal Action

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Awareness to Specific Exposure Concerns

For decades, general health and science communication has served as a foundation for public understanding of medical conditions and treatment options. This legacy context has traditionally focused on broad wellness principles, disease prevention, and the responsible use of therapeutic interventions. Within this framework, discussions of medication side effects have been framed as part of informed patient decision-making, emphasizing the balance between benefits and risks. As the landscape of pharmaceutical treatments evolves, a specific area of concern has emerged that requires careful attention: the relationship between certain widely prescribed medications and unexpected gastrointestinal complications. In particular, the class of drugs known as GLP-1 receptor agonists, including the medication Ozempic, has been associated with reports of delayed gastric emptying and related symptoms. This condition, known as gastroparesis, can significantly impact quality of life and may require medical intervention. The transition from general health awareness to this specific exposure concern is marked by a growing recognition that individuals who have used Ozempic and subsequently developed gastroparesis symptoms may face unique challenges. These challenges include navigating the healthcare system, understanding potential long-term implications, and exploring legal avenues for accountability.

Find Out If You Qualify for Compensation →

Understanding Gastroparesis and Its Link to Ozempic

Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which food leaves the stomach. The condition can significantly impair quality of life and may result in malnutrition, dehydration, and metabolic disturbances. Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes. Its pharmacology involves slowing gastric emptying as part of its mechanism to reduce postprandial glucose excursions. However, this effect can become pathological in some patients, contributing to the development or exacerbation of gastroparesis. Clinical trial data indicate that gastrointestinal adverse reactions occur more frequently among patients receiving Ozempic than placebo. In placebo-controlled trials, gastrointestinal adverse reactions were reported in 15.3% of placebo patients, compared to 32.7% of those on Ozempic 0.5 mg and 36.4% on Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) versus Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with a frequency of less than 5% associated with Ozempic include dyspepsia (placebo 1.9%, Ozempic 0.5 mg 3.5%, Ozempic 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data underscore the potential for Ozempic to induce or worsen gastric symptoms that overlap with gastroparesis.

Mechanisms and Risk Considerations for Ozempic-Associated Gastroparesis

Mechanistically, GLP-1 receptor agonists like semaglutide delay gastric emptying by inhibiting antral contractions and stimulating pyloric tone. In susceptible individuals, this pharmacodynamic effect may lead to sustained impairment of gastric motility, resulting in gastroparesis. The timeline between exposure and documented harm can vary; some patients experience symptoms during dose escalation, while others may develop symptoms after prolonged use. The label notes that the majority of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), but chronic symptoms may persist or worsen over time. Risk considerations for affected patients include the adequacy of warnings regarding Ozempic and gastroparesis. The prescribing information for Ozempic does not explicitly list gastroparesis as a warning or precaution. Instead, it groups gastrointestinal adverse reactions under a general category, with specific mention of dyspepsia, gastroesophageal reflux disease, and gastritis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Serious hypersensitivity reactions, such as anaphylaxis and angioedema, are separately warned (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), but the potential for gastroparesis is not highlighted. This gap in explicit warning may be relevant for patients who developed gastroparesis after using Ozempic and were not adequately informed of the risk.

Legal Considerations and Eligibility for Ozempic Gastroparesis Lawsuits

Attorney-related considerations for affected patients involve evaluating whether the manufacturer provided sufficient warnings to healthcare providers and patients. The absence of a specific gastroparesis warning in the label could be a point of contention in legal claims. Patients who have experienced severe gastrointestinal symptoms leading to hospitalization, nutritional deficiencies, or long-term disability may have grounds for a lawsuit. Key factors include the timeline between starting Ozempic and the onset of gastroparesis symptoms, as well as any documented evidence of delayed gastric emptying. The discontinuation rates due to gastrointestinal adverse reactions (3.1% for 0.5 mg and 3.8% for 1 mg) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166) indicate that a subset of patients experiences significant adverse effects, which may support claims of harm. In summary, the evidence links Ozempic to gastrointestinal adverse reactions that can manifest as or contribute to gastroparesis. The label data show a higher incidence of such reactions compared to placebo, with dose-dependent effects. However, the lack of a specific gastroparesis warning may raise questions about the adequacy of risk communication. Patients who have suffered from gastroparesis after using Ozempic should consult with an attorney to assess their eligibility for legal action, considering the clinical presentation, exposure timeline, and documented harm.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is gastroparesis and how is it diagnosed?

How does Ozempic cause or worsen gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying as part of its mechanism. In susceptible individuals, this effect can become pathological, leading to sustained impairment of gastric motility and resulting in gastroparesis. Clinical trial data show a higher incidence of gastrointestinal adverse reactions in patients taking Ozempic compared to placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

What are the eligibility criteria for an Ozempic gastroparesis lawsuit?

Eligibility typically requires documented exposure to Ozempic, a confirmed diagnosis of gastroparesis via gastric emptying scintigraphy, and evidence that the gastroparesis developed after starting Ozempic. Patients who experienced severe symptoms leading to hospitalization, nutritional deficiencies, or long-term disability may have stronger claims. The lack of a specific gastroparesis warning in the label may be a key factor.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Label

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.